Trial Profile
A Phase I/II Study of E7389 Halichondrin B Analog (NSC 707389; IND 64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Feb 2024 Planned End Date changed from 31 Dec 2023 to 1 Aug 2024.
- 09 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 1 Aug 2024.
- 21 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.